Ambryon Biosciences

Autologous Stem Cell Treatment for Chronic Lung Disease Study

Observational single-arm study of autologous stem cell therapy (blood or bone marrow cells) in 207 patients with COPD or interstitial lung disease: 121 of 148 respondents reported better quality of life at 3 months; FEV1 was reported for only 5.

StatusCompleted
Primary Endpoint ResultInconclusive
Enrollment207
Start Date2016-04-01
Primary Completion Date2017-06-01

Results Summary

This single-arm observational study enrolled 207 patients with COPD or ILD; 148 completed the 3-month quality-of-life survey, 124 the 6-month survey, and 59 were lost to follow-up. Quality of life was measured with the Clinical COPD Questionnaire (CCQ); the definition of improvement is not stated. Across all diagnoses, 121 of 148 respondents (82%) reported improvement at 3 months and 90 of 124 (73%) at 6 months. In COPD, 102 of 120 (85%) at 3 months and 79 of 101 (78%) at 6 months; in ILD, 20 of 28 (71%) and 13 of 23 (57%). Among COPD patients, the mean FEV1 change at 6 months was 12.8% (full range 0 to 100) in the 5 who returned spirometry. Posted adverse events: 4 of 207 died (causes not described), serious adverse events in 0 of 207, and non-serious events in 10 of 207 (dizziness 7, hypotension 2, bradycardia not procedure related 1).

Design Implications

Uncontrolled, self-reported outcomes cannot show whether returning autologous blood or bone marrow cells helps patients with COPD or ILD, so these results are not evidence of efficacy for the cell product. A pulmonary cell therapy trial needs a randomized or sham-controlled arm, a characterized product (cell type, cell number, PRP content) and an objective primary endpoint such as FEV1, with a plan to obtain the tests: only 5 COPD patients returned 6-month spirometry. The posted non-serious events (dizziness after blood collection, hypotension after bone marrow harvest) were linked to collection, not infusion, so collection route is a safety variable to compare. Cause and relatedness of deaths must be recorded. Analyze COPD and ILD separately rather than pooling.

Rationale

Lung Institute returns a patient's own cells to the circulation the same day: cells are harvested from peripheral blood, or from bone marrow plus peripheral blood, isolated together with platelet-rich plasma (PRP), and returned through peripheral circulation. The registry states no mechanism, cell type, cell dose or molecular target. The implied premise is that autologous cells and PRP support repair of lung tissue damaged by chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD). The registered hypotheses were safety, a perceived improvement in quality of life, and a higher FEV1 in COPD.

Limitations

Single-arm, open-label, uncontrolled study of self-referred, self-funded patients; no success criterion was stated. Quality of life was self-reported and improvement was not defined. 59 of 207 were lost to follow-up and FEV1 came from 5 patients. Posted 6-month subgroup counts (79 COPD + 13 ILD = 92) do not match the all-diagnoses count (90). 4 deaths are listed alongside 0 serious adverse events. No publications are linked.

Registry record

The purpose of the Lung Institute is to collect and isolate a patient's own cells and platelet rich plasma (PRP) and deliver the product back to the patient the same day. Lung Institute's treatment is limited to self-funded patients with chronic lung disease- chronic obstructive pulmonary disease (COPD) and restrictive lung diseases such as pulmonary fibrosis (PF) and interstitial lung disease (ILD). The patient's cells and platelet rich plasma are harvested through venous or bone marrow collection techniques. The hypothesized outcomes of therapy are safety and minimization of adverse events, a perceived improvement in the patient's lung condition (to be determined by their perceived quality of life), an improvement in the FEV1 among COPD patients, the ability to reduce supplemental oxygen use, the ability to function well without the use of rescue inhalers, reduction of secondary pulmonary infections, reduction in emergency room visits and exacerbations related to their disease.

Official TitleAutologous Stem Cell Treatment for Chronic Lung Disease Study
Primary OutcomesChange in FEV1 From Baseline Among COPD Patients, Number of Participants Reporting an Improvement in 3 Month-Post Treatment QOL Scores, All Diagnoses, Number of Participants Reporting an Improvement in 6 Month-Post Treatment QOL Scores, All Diagnoses
KeywordsShortness of breath, Breathlessness, Stem cells, Platelet rich plasma, Quality of life, Pulmonary Function
Registry Last Updated2018-10-15
Results First Posted Date2017-10-25
Minimum Age16 Years
Modalitiescell_therapy
Intervention NamesCell therapy
Has ResultsYes
Enrollment TypeActual
CountriesUnited States
Intervention Typesprocedure
Study TypeObservational
Healthy VolunteersNo
Condition TermsCOPD, Interstitial Lung Disease, Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial, Dyspnea
Completion Date2017-06-09
Lead Sponsor ClassIndustry
Eligibility SexAll

Eligibility Criteria

Inclusion Criteria:

  • Patients are included in treatment by self-referral and after consultation with a designated patient coordinator who determines initial eligibility, and then by the clinic nurse practitioner or physician of Lung Institute who determines final eligibility for inclusion. All eligible treated patients are eligible for the study.

Exclusion Criteria:

  • Patients who are unable to provide informed consent, pregnant patients, prisoners, non-English speakers, patients with a history of cancer within the past 5 years, patients with active tuberculosis or pneumonia. In addition, patients on prescribed blood thinners, with a history of breast or prostate cancer of any time frame or with a history of osteoporosis are excluded from the bone marrow harvest option.

Identifiers & revision